Expertise in
1
conditions

Dr. Keren Sturtz

Oncology
The Christ Hospital
2139 Auburn Ave, 
Cincinnati, OH 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
1
conditions
The Christ Hospital
2139 Auburn Ave, 
Cincinnati, OH 

Overview

Keren Sturtz is an Oncologist practicing medicine in Cincinnati, Ohio.

Dr. Sturtz is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Hairy Cell Leukemia (HCL), Breast Cancer, Tongue Cancer, and Lung Cancer.

She is actively involved in clinical research, co-authoring 11 peer reviewed articles and participating in 114 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in CO

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

The Christ Hospital
2139 Auburn Ave, Cincinnati, OH 45219

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

114 Clinical Trials

Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
Enrollment Status: Recruiting
Publish Date: June 18, 2026
Intervention Type: Other, Biological, Drug
Study Drugs: Daratumumab, Dexamethasone, Lenalidomide
Study Phase: Phase 3
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: June 18, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
Tomosynthesis Mammographic Imaging Screening Trial (TMIST)
Tomosynthesis Mammographic Imaging Screening Trial (TMIST)
Enrollment Status: Active_not_recruiting
Publish Date: June 18, 2026
Intervention Type: Other, Procedure
Study Phase: Phase 3
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Enrollment Status: Active_not_recruiting
Publish Date: June 18, 2026
Intervention Type: Drug
Study Drugs: Abiraterone acetate, Antiandrogen therapy, Cabazitaxel, Prednisone
Study Phase: Phase 2
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Drug, Biological, Procedure
Study Drugs: Bendamustine Hydrochloride, Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Obinutuzumab, Prednisone, Umbralisib, Vincristine Sulfate
Study Phase: Phase 2
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
View 9 Less Clinical Trials

11 Total Publications

A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation.
A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation.
Journal: Cancer discovery
Published: January 18, 2024
Similar Doctors
Expertise in
22
conditions
Dr. Kasiani Myers
Hematology | Oncology
Expertise in
22
conditions
Dr. Kasiani Myers
Hematology | Oncology
Referral may be required

Cincinnati Children's Hospital Medical Center

3333 Burnet Ave, 
Cincinnati, OH 
 (1.4 miles away)
513-636-4266
Languages Spoken:
English
See accepted insurances

Kasiani Myers is a Hematologist and an Oncologist practicing medicine in Cincinnati, Ohio. Dr. Myers is highly rated in 22 conditions, according to our data. Her clinical expertise encompasses Shwachman-Diamond Syndrome, Congenital Aplastic Anemia, Fanconi Anemia, Aplastic Anemia, and Bone Marrow Transplant.

Expertise in
17
conditions
Dr. Theodosia Kalfa
Hematology | Oncology
Expertise in
17
conditions
Dr. Theodosia Kalfa
Hematology | Oncology
Referral may be required

Office

3333 Burnet Ave # 7015, 
Cincinnati, OH 
 (1.4 miles away)
513-636-4266
Languages Spoken:
English
See accepted insurances

Theodosia Kalfa is a Hematologist and an Oncologist practicing medicine in Cincinnati, Ohio. Dr. Kalfa is highly rated in 17 conditions, according to our data. Her clinical expertise encompasses Hereditary Spherocytosis, Hereditary Pyropoikilocytosis, Hemolytic Anemia, Congenital Hemolytic Anemia, and Splenectomy.

Expertise in
22
conditions
Dr. Stella Davies
Hematology | Oncology
Expertise in
22
conditions
Dr. Stella Davies
Hematology | Oncology
Referral may be required

Office

3333 Burnet Ave # 7015, 
Cincinnati, OH 
 (1.4 miles away)
513-636-4266
Languages Spoken:
English
See accepted insurances

Stella Davies is a Hematologist and an Oncologist practicing medicine in Cincinnati, Ohio. Dr. Davies is highly rated in 22 conditions, according to our data. Her clinical expertise encompasses Congenital Aplastic Anemia, Fanconi Anemia, Shwachman-Diamond Syndrome, Bone Marrow Transplant, and Bone Graft.

Frequently Asked Questions about Dr. Keren Sturtz

How do I make an appointment with Dr. Keren Sturtz?

You can book an appointment with Dr. Keren Sturtz by calling their office at 513-321-4333. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Keren Sturtz a top-rated expert for Hairy Cell Leukemia (HCL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Keren Sturtz is classified as an Advanced expert for Hairy Cell Leukemia (HCL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Keren Sturtz specialize in?

While Dr. Keren Sturtz is a Oncology, they have specific expertise in Hairy Cell Leukemia (HCL), Breast Cancer, and Tongue Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Keren Sturtz participate in research or clinical trials?

Yes. Dr. Keren Sturtz has published 11 articles and abstracts on conditions like Hairy Cell Leukemia (HCL). You can view a list of Dr. Keren Sturtz's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Keren Sturtz accept my insurance?

Dr. Keren Sturtz accepts most major insurance plans, including Cigna and Humana. We recommend calling the office directly at 513-321-4333 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sturtz's expertise for a condition
ConditionClose
      View All 36 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile